Pilot Study of Hypertrophic Cardiomyopathy & Implantable Cardioverter Defibrillator Assessment: (Subcutaneous vs Transvenous)

Exclusion Criteria

• •Patients with sustained ventricular tachycardia less than 170 bpm
• •Patients having an indication for pacing therapy. E.g. sick sinus syndrome.
• •Patients failing appropriate QRS/T-wave sensing with the automated S-ICD ECG automated patient screening provided by Boston Scientific
• •A minimum of 1 sensing vector passing in supine, standing.
• •Patients with incessant ventricular tachycardia
• •Patients who have had a previous ICD implant
• •Patient who receives cardiac contractility modulation therapy or are likely to receive cardiac contractility modulation therapy
• •Patients with a serious known concomitant disease with a life expectancy of less than one year
• •Patients with circumstances that prevent follow-up (no permanent home or address, transient, etc.)
• •Patients who are unable to give informed consent
• •Patients who are not suitable for TV-ICD implantation, according to the discretion of the physician, are not screened for enrolment (SVC occlusion).